Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) has successfully completed its exchange offer for all outstanding shares of common stock of Genzyme Corporation (NASDAQ: GENZ).

Pfizer and Kohlberg Kravis Roberts & Co L.P. (together with its affiliates, "KKR") have entered into an agreement whereby an affiliate of KKR will acquire Pfizer's Capsugel business for $2.375 billion in cash.

Boehringer Ingelheim announced the study outline for the pivotal Phase III clinical trials designed to evaluate BI 201335, its investigational once-daily oral protease inhibitor, in both treatment-naïve and -experienced patients with chronic genotype-1 hepatitis C virus (HCV), the most challenging genotype to treat.

GlaxoSmithKline (NYSE:GSK) published a list of payments made during 2010 for clinical research studies led by U.S. healthcare professionals.

Pfizer Inc. released a report detailing the company's financial interactions with health care professionals and researchers in 2010.

Nycomed announced plans for an international phase III/IV study investigating the effect of Daxas® versus placebo on exacerbation rates in COPD patients who are concomitantly treated with fixed combination long-acting-ß2-agonists (LABA) and inhaled corticosteroids (ICS),

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced that the registration statement relating to the Contingent Value Rights (CVRs) offered to Genzyme shareholders as part of sanofi-aventis' agreement to acquire Genzyme has been declared effective by the U.S. Securities and Exchange Commission.